RecruitingPhase 2NCT05788679
A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS
Studying Myelodysplastic/myeloproliferative disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Karolinska University Hospital
- Principal Investigator
- Magnus Tobiasson, PhDKarolinska University Hospital
- Intervention
- Azacitidine(drug)
- Enrollment
- 200 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (1)
- Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
Collaborators
Nordic MDS Group
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05788679 on ClinicalTrials.govOther trials for Myelodysplastic/myeloproliferative disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT05564390MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)National Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06532084Sorafenib Relapase Prophylaxis After HCT With PTBCy RegimenSt. Petersburg State Pavlov Medical University
- RECRUITINGPHASE2NCT04493164CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeM.D. Anderson Cancer Center
See all trials for Myelodysplastic/myeloproliferative disease →